News & Insights

BioTech
DYN

Dyne Therapeutics Reports Positive Data From ACHIEVE Study Of DYNE-101 In Myotonic Dystrophy Type 1

January 10, 2025 — 06:58 am EST

Written by RTTNews.com for RTTNews ->

(RTTNews) - Dyne Therapeutics, Inc. (DYN) Friday announced encouraging data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1).

Myotonic dystrophy type 1 is a genetic disease that causes progressive muscle weakness and loss.

The company said results from the study showed that DYNE-101 continued to demonstrate a compelling impact on key disease biomarkers.

Dyne plans to initiate a Registrational Expansion Cohort in ACHIEVE, with submission for accelerated approval expected in the first half of 2026.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

BioTech
RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source ->

Stocks mentioned

DYN

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

  • •

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.